Lebwohl, M.; Gooderham, M.; Warren, R. B.; Thaçi, D.; Foley, P.; Gottlieb, A. B.; Hippeli, L.; Kisa, R. M.; Banerjee, S.; Griffiths, C. E. Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Absolute PASI Outcomes Over 52 Weeks in the Phase 3 POETYK PSO-1 Trial. J of Skin 2023, 7, s239.